News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AIT Therapeutics Reports Second Quarter 2017 Financial Results



8/11/2017 10:37:52 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
REHOVOT, Israel and NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced financial results for the three- and six-months ended June 30, 2017.

Operational and Financial Highlights include:

Enrolled the first patient in the Nitric Oxide for NTM abscessus (NO-NTM abscessus) Phase 2 clinical trial in patients with Mycobacterium Abscessus Complex (MABSC), the most severe form of nontuberculous mycobacteria (NTM), with data expected in the fourth quarter of 2017.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES